1996
Hartington Business S.L. is founded in Spain.
Work is started on a compound to cure rhinosinusitis.
1998
Iveriapharma is founded in Georgia, enabling the clinical trials for Sinuforte® to start.
2002
Construction of new production plant in Georgia is completed, equipped with the latest production lines and the most advanced manufacturing resources. Investigation into the treatment of herpes is initiated.
Introduction of Nasodren® (Sinuforte®) in Georgia, Azerbaijan, Ukraine, Kazakhstan and Belarus.
2003
Favourable results from the preclinical trials; clinical trials on the treatment of herpes are initiated.
2004
Hartington Pharmaceutical S.L. is founded in Spain.
2005
Launch of Sinuforte® in Russia.
2006
Hartington enters the Western European pharmaceutical market with the Spanish Licence for Fluirespira Forte® from Zambon Group.
2007
Enters the pharmaceutical market of the following countries: Germany, Poland, and Slovenia. Hartington Pharma Ltd is set up for the manufacture of Nasodren®.
2009
Important documents released such as US clinical trial (434-083) conclusion, Nasodren® monograph, newsletter, consumer focus, Nasodren® web page, sales folder. Expansion of Nasodren® to new countries such as Greece, Romania and Bulgaria.
2010
Introduction of Nasodren® in more new markets: the Netherlands, Luxemburg, Czech Republic, Baltic countries and Austria. Introduction of the consumer corporate campaign.
2011
Launch of Nasodren® in Australia and Arabia Saudi.
2012
Introduction of Nasodren® in Belgium, France, Switzerland, Sweden and Croatia.
2013
Launch of Nasodren® in Serbia and Finland.
2014
Launch of Nasodren® in Turkmenistan and Spain.
